Efficacy and safety of irreversible electroporation combined with immunotherapy in treatment of unresectable pancreatic cancer： A Meta-analysis
Journal Title: Journal of Clinical Hepatology - Year 2024, Vol 40, Issue 11
Abstract
[Objective] To systematically review the safety and efficacy of irreversible electroporation （IRE） combined with immunotherapy in patients with unresectable pancreatic cancer. [Methods] This study was conducted according to the PRISMA guideline， with a PROSPERO registration unmber of CRD42024531984. Datebases including PubMed， Embase the Cochrane Library， Web of Science， CNKI， Wanfang Data， and VIP were searched for related articles on IRE combined with immunotherapy for unresectable pancreatic cancer published up to February 2024. The articles were screened and related data were extracted according to the established inclusion and exclusion criteria， and the quality of the articles was assessed. Review Manager 5.3 and Stata 17.0 software were used to perform the meta-analysis. [Results] Six studies were finally included， with three prospective studies， two retrospective studies， and one randomized controlled trial. There were 376 patients with unresectable pancreatic cancer in total， among whom there were 222 patients in the IRE group and 154 patients in the IRE+immunotherapy group. The meta-analysis showed that compared with IRE alone， IRE combined with immunotherapy significantly prolonged progression-free survival （hazard ratio ［HR］=0.82， 95% confidence interval ［CI］： 0.72 — 0.92， P=0.001） and overall survival （HR=0.86， 95%CI： 0.80 — 0.93， P=0.000 1）， increased T lymphocyte count in the patients （mean difference=217.93， 95%CI： 192.87 — 242.99， P<0.000 01）， and improved the immune function of patients. However， there were no significant differences between the two groups in reducing the incidence rate of adverse events （odds ratio ［OR］=1.43， 95%CI： 0.76 — 2.72， P=0.27） and improving the objective remission rate of patients （OR=1.49， 95%CI： 0.87 — 2.56， P=0.15）. [Conclusion] IRE combined with immunotherapy is safe and effective in patients with unresectable pancreatic cancer and can significantly improve overall survival and progression-free survival and enhance immune function， with little effect on objective remission rate and the incidence rate of adverse events.
Authors and Affiliations
Jian YE, Junfeng YANG, Liwen DU, Jiansheng LIU
Keywords
Related Articles
- EP ID EP753502
- DOI 10.12449/JCH241122
- Views 8
- Downloads 1
Recurrent hyperlipidemic acute pancreatitis： Etiology and prevention and treatment strategies
The incidence rate of hyperlipidemic acute pancreatitis （HLAP） is gradually increasing， with the features of young age， severe conditions， frequent recurrence， and poor prognosis， and recurrent HLAP has become a d...
Efficacy and safety of irreversible electroporation combined with immunotherapy in treatment of unresectable pancreatic cancer： A Meta-analysis
[Objective] To systematically review the safety and efficacy of irreversible electroporation （IRE） combined with immunotherapy in patients with unresectable pancreatic cancer. [Methods] This study was conducted accordi...
Theoretical and clinical practice of metabolic associated fatty liver disease based on the theory of “six stagnation diseases”
Metabolic associated fatty liver disease （MAFLD） has become the most common liver disease in the world， including simple hepatic steatosis， steatohepatitis， liver fibrosis/cirrhosis， and liver cancer， and it is of...
Pancreatic hamartoma： A case report
Pancreatic hamartoma is a rare benign lesion of the pancreas characterized by a lack of typical clinical symptoms and imaging features， which leads to the difficulty in diagnosis before surgery. Since surgical intervent...
Efficacy and safety of camrelizumab monoclonal antibody combined with molecular-targeted therapy in elderly patients with advanced hepatocellular carcinoma
[Objective] To investigate the efficacy and safety of camrelizumab monoclonal antibody combined with molecular-targeted therapy in elderly patients with unresectable or advanced hepatocellular carcinoma （HCC）. [Methods...